1. Scrip
  2. >>Business
  3. >>Financing

Evommune Looks To Advance Broad Pipeline Of Autoimmune Drugs

 
• By Jessica Merrill

Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.

Emerging Company Profile: Evommune
Evommune is developing drugs for inflammatory conditions • Source: Shutterstock

Evommune, Inc. recently closed a $57.5m series B financing that it believes will position the company to advance multiple novel drugs for a variety of autoimmune diseases toward value-creating catalysts. The company’s lead asset is a topical IRAK4 inhibitor in Phase IIa development for atopic dermatitis, but the company has other novel systemic drugs it is aiming to bring into the clinic in the near-term.

“Our goal is to continue to drive a pipeline and not just have one program with a binary outcome,”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.